UK Orders 10.6 Million Doses of GSK/Biota Relenza To Cope With Tamiflu-resistant Flu
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-based Biota Holdings announced recently that partner GlaxoSmithKline has been awarded a contract by the UK Department of Health for 10.6 million treatment courses of flu drug Relenza (zanamivir). Relenza was developed by Biota and is marketed by GSK
You may also be interested in...
Australia’s Biota To Become U.S. Company Through Merger With Nabi
Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.
Daiichi Sankyo Exercises Option With Aussie Biotech Biota For Second-Gen Flu Drug
Biota would get royalties on Japanese sales and share rest-of-world commercialization rights 50/50 with Daiichi.
Daiichi Sankyo Exercises Option With Aussie Biotech Biota For Second-Gen Flu Drug
Biota would get royalties on Japanese sales and share rest-of-world commercialization rights 50/50 with Daiichi.